Kidney Week 2022 | MIMS Malaysia

Stopping RAS inhibitors does not slow eGFR decline in advanced CKD

Roshini Claire Anthony, 20221216180001

In patients with advanced chronic kidney disease (CKD), discontinuing renin–angiotensin system (RAS) inhibitor therapy does not slow down decline in estimated glomerular filtration rate (eGFR), a recent trial showed.

Post hoc data boost voclosporin efficacy for severe lupus nephritis

Audrey Abella, 20221214100000

In the post hoc analysis of the AURORA 1 and 2 trials, the novel calcineurin inhibitor voclosporin was effective in achieving complete renal response (CRR)* in individuals with severe lupus nephritis** (LN).

Potassium monitoring device ups QoL in dialysis patients

Elvira Manzano, 20221212000000

Using a real-time potassium monitoring device saves money and improves quality of life (QoL) in haemodialysis patients in a study presented at Kidney Week 2022.

CV benefits of dapagliflozin evident regardless of baseline kidney function

Roshini Claire Anthony, 20221211110001

The cardiovascular (CV) benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is evident regardless of baseline kidney function, according to an analysis of the DELIVER* trial presented at Kidney Week 2022.

No reduction in CKD progression with veverimer

Veverimer does not delay CKD progression

Roshini Claire Anthony, 20221207180001

Treatment with once-daily veverimer did not delay chronic kidney disease (CKD) progression, according to the results of the phase III VALOR-CKD trial.

DUET OLE supports long-term nephroprotection of sparsentan for FSGS patients

Audrey Abella, 20221207031637

Results from the open-label extension (OLE) period of the phase II DUET trial demonstrated the long-term nephroprotective potential and safety of sparsentan for individuals with focal segmental glomerulosclerosis (FSGS).

No CV benefits with cooler dialysate

Elvira Manzano, 20221127000000

The use of a cooler dialysate during maintenance haemodialysis does not offer cardiovascular (CV) benefits to patients in the MyTEMP trial.